The article focuses on treatment options like checkpoint inhibitors and signal transduction inhibitors for recurrent melanoma and stage III and IV. It discusses how treatment is decided on the basis of gene mutations including positive with BRAF V600 activating mutation, combination therapy with BRAF/MEK inhibitors is needed.